{"version":"1.0","type":"link","title":"Neoadjuvant ipilimumab plus nivolumab in melanoma: 5-year survival and biomarker analysis from the phase 2 PRADO-trial.","author_name":"Hoeijmakers LL 외","author_url":"https://prs-insight.online/author/Hoeijmakers%20LL","provider_name":"PRSinsight","provider_url":"https://prs-insight.online","thumbnail_url":"https://prs-insight.online/og/paper/167973","thumbnail_width":1200,"thumbnail_height":630}